Literature DB >> 18165235

Regulation of RON tyrosine kinase-mediated invasion of breast cancer cells.

Amalraj Thangasamy1, Jessica Rogge, Sudhakar Ammanamanchi.   

Abstract

RON (recepteur d'origine nantais), a tyrosine kinase receptor for macrophage-stimulating protein (MSP) was implicated in tumor progression. However, it was not investigated how this important oncogene is regulated. We show that MSP promotes invasion of MDA MB 231 and MDA MB 468 but not MCF-7 breast cancer cells. Reverse transcription-PCR and Western analysis indicated the expression of RON message and protein, respectively, in MDA MB 231 and MDA MB 468 cells but not in MCF-7 cells. RON expression correlated with Sp1 expression. Initial analysis of a 1.2-kb and 400-bp RON promoter in MDA MB 231 and MDA MB 468 cells suggested the presence of all the necessary regulatory elements within 400 bp from the transcription start site. Site-directed mutagenesis of the 400-bp RON promoter revealed that the overlapping Sp1 sites at-94 (Sp1-3/4) and Sp1 site at -113 (Sp1-5) are essential for RON gene transcription. Electrophoretic mobility shift assays and chromatin immunoprecipitation analysis indicated that Sp1 binding to these sites is required for RON promoter activity. Ectopic Sp1 expression in Sp1 null SL2 cells confirmed the involvement of these Sp1 sites in the regulation of oncogenic RON tyrosine kinase. Treatment of MDA MB 231 cells with mithramycin A, an inhibitor of Sp1 binding, or siRNA knock-down of Sp1 blocked RON gene expression and MSP-mediated invasion of MDA MB 231 cells. This is the first report demonstrating a clear link between Sp1-dependent RON tyrosine kinase expression and invasion of breast carcinoma cells.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18165235     DOI: 10.1074/jbc.M706957200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  8 in total

1.  Mithramycin A suppresses expression of the human melanoma-associated gene ABCB8.

Authors:  Iwona Sachrajda; Marcin Ratajewski
Journal:  Mol Genet Genomics       Date:  2010-11-03       Impact factor: 3.291

Review 2.  MSP-RON signalling in cancer: pathogenesis and therapeutic potential.

Authors:  Hang-Ping Yao; Yong-Qing Zhou; Ruiwen Zhang; Ming-Hai Wang
Journal:  Nat Rev Cancer       Date:  2013-07       Impact factor: 60.716

3.  Novel function of transcription factor Nrf2 as an inhibitor of RON tyrosine kinase receptor-mediated cancer cell invasion.

Authors:  Amalraj Thangasamy; Jessica Rogge; Naveen K Krishnegowda; James W Freeman; Sudhakar Ammanamanchi
Journal:  J Biol Chem       Date:  2011-07-28       Impact factor: 5.157

4.  RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma.

Authors:  Daniel V T Catenacci; Gustavo Cervantes; Soheil Yala; Erik A Nelson; Essam El-Hashani; Rajani Kanteti; Mohamed El Dinali; Rifat Hasina; Johannes Brägelmann; Tanguy Seiwert; Michele Sanicola; Les Henderson; Tatyana A Grushko; Olufunmilayo Olopade; Theodore Karrison; Yung-Jue Bang; Woo Ho Kim; Maria Tretiakova; Everett Vokes; David A Frank; Hedy L Kindler; Heather Huet; Ravi Salgia
Journal:  Cancer Biol Ther       Date:  2011-07-01       Impact factor: 4.742

5.  Recepteur d'origine nantais tyrosine kinase is a direct target of hypoxia-inducible factor-1alpha-mediated invasion of breast carcinoma cells.

Authors:  Amalraj Thangasamy; Jessica Rogge; Sudhakar Ammanamanchi
Journal:  J Biol Chem       Date:  2009-03-23       Impact factor: 5.157

6.  Therapeutic Considerations for Ron Receptor Expression in Prostate Cancer.

Authors:  Nicholas E Brown; Camille Sullivan; Susan E Waltz
Journal:  EMS Cancer Sci J       Date:  2018-07-30

Review 7.  Roles of c-Met and RON kinases in tumor progression and their potential as therapeutic targets.

Authors:  Katherine Chang; Anand Karnad; Shujie Zhao; James W Freeman
Journal:  Oncotarget       Date:  2015-02-28

8.  Knockdown of RON receptor kinase delays but does not prevent tumor progression while enhancing HGF/MET signaling in pancreatic cancer cell lines.

Authors:  S Zhao; L Cao; J W Freeman
Journal:  Oncogenesis       Date:  2013-10-07       Impact factor: 7.485

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.